子宫腺肌病是一种常见的妇科疾病，其导致的缺铁性贫血对患者健康构成了严重威胁。该病主要影响30~50岁的育龄期女性，引发痛经、月经失调等症状，长期的异常子宫出血进一步引发缺铁性贫血。缺铁性贫血不仅加剧了患者的临床症状，还显著降低了患者生活质量。近年来，针对子宫腺肌病合并缺铁性贫血的治疗方案取得了诸多进展。药物治疗方面，止血药物如促性腺激素释放激素激动剂（GnRH-a）、左炔诺孕酮宫内释放系统（LNG-IUS）和口服孕激素类药物被广泛用于控制症状，同时铁剂补充与促进铁吸收的药物成为纠正贫血的关键。手术治疗方面，子宫腺肌病病灶切除术和子宫切除术等手术方式的优化，为患者提供了更多有效的治疗选择。子宫腺肌病患者往往需要个体化综合治疗，结合药物治疗和手术治疗，能够更有效地控制子宫腺肌病的症状，减少手术并发症，同时提高患者的血红蛋白水平和生活质量。

Adenomyosis is a common gynecological disease，and the iron-deficiency anemia caused by it poses a serious threat to the health of patients. This disease mainly affects women of childbearing age between 30 and 50 years old，causing symptoms such as dysmenorrhea and menstrual disorders. Long-term abnormal uterine bleeding further triggers iron-deficiency anemia. Iron-deficiency anemia not only exacerbates the clinical symptoms of patients，but also significantly reduces patients’ quality of life. In recent years，there’s significant progress in the treatment of adenomyosis combined with iron-deficiency anemia. In terms of drug therapy，hemostatic drugs such as GnRH-a，LNG-IUS，and oral progesterone drugs are widely used to control symptoms，while iron supplements and the drugs that promote iron absorption have become key to correcting anemia. In terms of surgical treatment，the optimization of surgical methods such as uterine adenomyomectomy and hysterectomy provides patients with more effective treatment options. Patients with adenomyosis often require individualized comprehensive treatment，which，combined with drug therapy and surgical treatment，can control the symptoms of adenomyosis more effectively，reduce surgical complications，and improve the patient's hemoglobin level and quality of life.